Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome (original) (raw)

Blood, 2011

Abstract

1725 Introduction: Immunotherapeutic strategies have been limited by the lack of known tumor restricted antigens and inadequate immune responses. In our Institution, an ongoing Phase I dose escalation study in 11 high risk MDS patients, who failed hypo-methylating agents, were enrolled in a K562-GMCSF-CD40 ligand transfected “bystander” vaccine, in combination with lenalidomide, and have shown promising responses.…

Emmanuel Berchmans hasn't uploaded this paper.

Let Emmanuel know you want this paper to be uploaded.

Ask for this paper to be uploaded.